Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma

Phase I, open label, dose-escalation, and safety study designed to assess the safety and biologic activity of the investigational agent CBL0137 in combination with standard of care drugs, ipilimumab and nivolumab in sequential cohorts of adult patients with locally advanced and metastatic melanoma who are candidates for immune checkpoint blockade and have tumors accessible for serial biopsies.

Trial Details

NCT ID
NCT05498792
Phase
EARLY_PHASE1
Sponsor
Fox Chase Cancer Center
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • CBL0137
  • Ipilimumab
  • Nivolumab
Locations (sample)
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362

Key Eligibility Criteria

  • Patients must have:
  • Pathologically proven stage III melanoma with one or more macroscopic lymph node metastases (measurable according to RECIST v. 1.1) amenable to bio…
  • Patients considered to have stage III or stage IV disease amenable to serial biopsies as determined by the treating physician. Note: patients with …
  • Patients must have disease amenable to and must be willing to undergo protocol-directed repeat biopsies and blood draws.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →